9. Figure 76-3 B-cell differentiation scheme and associated B-cell neoplasms. CLL cells can be at a pre-germinal center (unmutated) and post-germinal center (mutated) stage of differentiation. B, B cell; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; LBL, lymphoblastic leukemia/lymphoma. Reifungsstufen von B Lymphozyten und maligne Transformation von Non-Hodgkin Lymphomen
10. Damle et al, Blood 1999 Einfluss des Ig-VH Mutationsstatus auf das Überleben von Patienten mit B-CLL
21. Tam, C. S. et al. Blood 2008;112:975-980 Verbesserung der Überlebenszeit in Abhängigkeit des Therapieregimes (M.D. Anderson)
22.
23. Ergebnisse der CLL-8 Studie (Hallek et al, Lancet 2010) Therapie FC R-FC Komplette Remission 21,8 % 44,1 % Progression 8,1 % 3,3 % Progressionsfreies Überleben 32,4 Monate 52,4 Monate Gesamtüberleben (nach 37,7 Monaten) 79,1 % 84,1 % Nebenwirkungen Grad 3-4 62,9 % 76% Infektionen 21,5% 25,5%
24. Progression free survival according to Binet stages p=0.44 Binet A p<0.000001 Binet stages A+B Binet stage C ORR 93,3% ORR 88,0% Hallek et al, ASH 2008
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37. Schetelig, J. et al. J Clin Oncol; 26:5094-5100 2008 Fig 1. Outcome after allogeneic hematopoietic stem-cell transplantation (HCT) in patients with 17p-chronic lymphocytic leukemia (CLL)
38.
Notas do Editor
Survival of patients receiving fludarabine (F), fludarabine and cyclophosphamide or mitoxantrone (FC/M), and FCR as initial therapy of CLL at the M. D. Anderson Cancer Center. Six-year overall survivals were 54%, 59%, and 77%, respectively.
Fig 1. Outcome after allogeneic hematopoietic stem-cell transplantation (HCT) in patients with 17p–chronic lymphocytic leukemia (CLL). (A) The probabilities of overall and progression-free survival in 44 patients with 17p–CLL at 3 years after allogeneic HCT were 44% (95% CI, 28% to 60%) and 37% (95% CI, 22% to 52%), respectively. (B) The cumulative incidences of relapse and nonrelapse mortality at 3 years were 30% (95% CI, 16% to 44%) and 32% (95% CI, 18% to 46%), respectively.